Explore /
Poster
/ Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer.

Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer.

Authors

Alice Markussen

Herlev and Gentofte Hospital, Department of Oncology, Herlev, Denmark;

Alice Markussen , Julia S. Johansen , Finn Ole Larsen , Susann Theile , Jane P. Hasselby , Gro Linno Willemoe , Torben Lorentzen , Kasper Madsen , Eva E. Wilken , Poul F. Geertsen , Claus Behrens , Inge Marie Svane , Dorte Nielsen , Inna Markovna Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02866383

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 545)

DOI

10.1200/JCO.2023.41.4_suppl.545

Abstract #

545

Poster Bd #

C15

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Gastrointestinal Cancers Symposium

$Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).$